Nasal influenza vaccine composition

Abstract

The present invention relates to a nasal mucosal spray delivery type influenza vaccine composition which is characterized in that the composition comprises a gel base including an influenza virus inactivated whole particle antigen and a carboxyvinyl polymer but does not comprise an adjuvant.

Description

technical field [0001] The invention relates to a nasal mucosa spray administration type influenza vaccine composition. Background technique [0002] Influenza is an acute respiratory infectious disease caused by influenza virus, especially in winter, which is prevalent every year. In addition, sometimes it becomes a worldwide pandemic, and there are many cases where the disease becomes severe and leads to death. Influenza is known to have a certain preventive effect through influenza vaccination, and the vaccination is widely performed before the epidemic period. [0003] In Japan, influenza vaccines are approved only for subcutaneous administration of inactivated protein components of influenza virus antigens, and currently, this split vaccine is used as a seasonal influenza vaccine. Such a subcutaneous inoculation vaccine is highly effective in preventing severe cases of influenza such as pneumonia, but has a low ability to induce antibodies in the mucous membrane of th...

AI Technical Summary

Problems solved by technology

[0007] As mentioned above, it is urgently desired to develop and put into practical use a nasal administration type vaccine as a next-generation influenza vaccine based on existing influenza vaccines administered subcutaneously or intramuscularly, but how to suppress the use of There are various problems in the face of practical application, such as the toxicity of the adjuvant

Images